Ginkgo Bioworks Holdings Inc Class (DNA) financials
Ginkgo Bioworks Holdings Inc Class revenue and earnings by year
Ginkgo Bioworks Holdings Inc Class's revenue was $170 million in the fiscal year to December 31, 2025, down 25.1% from the year before. Net income was -$313 million, -183.8% of revenue. Since the fiscal year to December 31, 2019, revenue has grown 21.0% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 7 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.17 | 0.23 | 0.25 | 0.48 | 0.31 | 0.08 | 0.05 |
| Revenue growth | -25.1% | -9.7% | -47.4% | 52.2% | 309.4% | 41.5% | — |
| Gross profit | 0.12 | 0.18 | 0.20 | 0.27 | 0.18 | 0.06 | — |
| Gross margin | 72.4% | 80.4% | 78.5% | 57.3% | 58.7% | 79.6% | — |
| Operating income | -0.32 | -0.56 | -0.86 | -2.21 | -1.83 | -0.14 | -0.07 |
| Operating margin | -185.3% | -246.5% | -343.8% | -462.4% | -582.6% | -178.8% | -132.1% |
| Net income | -0.31 | -0.55 | -0.89 | -2.10 | -1.83 | -0.13 | -0.12 |
| Net margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | -220.2% |
| Diluted EPS | -$5.64 | -$10.54 | -$18.37 | -$50.20 | -$56.00 | — | — |
| Free cash flow | -0.18 | -0.38 | -0.33 | -0.30 | -0.31 | -0.19 | -0.07 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open DNA in Markets.
See also: DNA returns
No forecast, no recommendation. This page describes Ginkgo Bioworks Holdings Inc Class from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.